跳至主要内容
临床试验/IRCT20080901001165N59
IRCT20080901001165N59已完成3 期

Investigating the efficacy and safety of Nivasha oral spray in controlling the symptoms of patients with COVID-19

anoalvand arad company0 个研究点目标入组 80 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
80

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 no limit(—)
性别
All

入选标准

  • Age: equal or more than 18 years;
  • The patient have written consciously and freely consent to participate in the study.
  • The patient's clinical symptoms (dry cough, shortness of breath, fever) confirm COVID-19.
  • Confirmed diagnosis of COVID-19, with RT-PCR confirmation.
  • Less than 7 days have passed since the onset of symptoms.

排除标准

  • History of allergy to this spray ingredients;
  • The patient is in another clinical trial at the same time;
  • The patient needs to be hospitalized;

研究者

发起方
anoalvand arad company

相似试验